New Orleans—The first clinical trial of a novel ultrasound technology shows that it can safely reposition stones in situ to make them more amenable to natural passage and treatment.
The approach can also provide useful diagnostic information in distinguishing a larger stone that would not pass from a cluster of much smaller, passable stones, according to the study's authors.
"We have completed the first clinical trial of this technology in 15 patients and have met the goals of the study. The primary goal was to demonstrate that we could move stones within the kidney in humans. We did that in 14 of 15 patients. Secondary goals were also achieved in that it was tolerated in the clinic setting without pain, and there were no adverse events related to the procedure," first author Jonathan Harper, MD, associate professor of urology at the University of Washington, Seattle, told Urology Times.
"By repositioning stones, we were able to facilitate stone passage in four of the six post-lithotripsy patients," he said.